Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


AZ boss in struggle over pay

Posted May 6 2021 PM

It's been one of those weeks for AstraZeneca CEO Pascal Soriot - first he copped a hammering from reporters over the company's troubled COVID-19 vaccine and now investors are trying to put the squeeze on his future pay cheques. 

Three investor advisory firms, Pirc, Glass Lewis and Institutional Shareholder Services (ISS), have raised a red flag over AstraZeneca's proposal to increase the maximum bonus and equities that Soriot can earn for 2021.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
Could access probe be for nothing?
Significant industry participation but what outcome?
Approvals Action
Injectable antibiotic ticked
Fresenius Kabi adds to Gram-positive options